CJC-1295: Research, FDA Status & What We Know

CJC-1295 is a laboratory-designed analogue of growth hormone-releasing hormone (GHRH), a hypothalamic signal that prompts the pituitary to release growth hormone. The research interest is straightforward: can scientists extend a naturally brief signal without simply administering growth hormone itself?

The confusing part is that CJC-1295 is not used consistently. FDA’s 2024 evaluation separated five bulk drug substances representing two active moieties: non-DAC CJC-1295 forms and CJC-1295 DAC forms. Certificates, nominations, research references, and commercial descriptions have sometimes mixed them together.

Shorter exposure

Often discussed online as “CJC-1295 without DAC” or modified GRF 1-29. FDA found no peer-reviewed human safety or effectiveness data for the evaluated non-DAC forms.

Albumin-linked, longer exposure

The DAC modification is designed to bind serum albumin. Published healthy-adult studies estimated a half-life measured in days and sustained GH/IGF-1 effects.

In peptide communities, the story is usually not “I want a laboratory change in GH.” People talk about feeling more energetic, recovering better, sleeping more deeply, looking leaner or fuller, and noticing changes in skin, hair, or overall vitality. CJC-1295 is also frequently discussed alongside another growth-hormone secretagogue.

Energy & recovery

Users may attribute better stamina, workout recovery, or general physical recovery to the peptide.

Body composition

Fat loss, a fuller or more muscular appearance, strength, and greater vascularity are recurring claims.

Sleep & well-being

Some reports emphasize deeper sleep, better mood, or a broad sense of vitality.

Skin, hair & aging

Improved skin tone or elasticity, hair and nail quality, bone density, and cognition are also discussed.

Natural GHRH is rapidly cleared, which limits prolonged experimental stimulation. CJC-1295 DAC adds a reactive group intended to form a bond with albumin, a circulating protein. That albumin association slows clearance and can sustain downstream signaling.

The molecule was developed by ConjuChem as part of an effort to create longer-acting bioconjugated medicines. Its early clinical program focused on pharmacokinetics and endocrine markers, not the broad wellness and performance claims that later spread online.

CJC-1295 acts upstream of growth hormone. By activating the GHRH receptor, it can prompt pituitary GH release; GH then stimulates downstream pathways, including hepatic IGF-1 production. In a small healthy-men study, GH pulses remained detectable one week after the long-acting analogue, while overall GH exposure and IGF-1 were higher.

Preserved pulsatility is scientifically interesting, but it should not be translated into “natural,” “risk-free,” or “no shutdown.” Sustained endocrine stimulation can have systemic effects, and FDA concluded that long-term human safety is unknown.

The strongest published evidence is pharmacodynamic: the studied long-acting material raised GH and IGF-1 in small groups of healthy adults. That is useful proof of biological activity, not proof that CJC-1295 treats a disease or delivers the outcomes promoted online.

• Human pharmacology · healthy adults

  Teichman et al., 2006

  Two short ascending-exposure studies enrolled healthy adults. A single administration increased mean GH for at least six days and mean IGF-1 for roughly nine to eleven days; repeated administrations produced cumulative IGF-1 effects. The estimated half-life was about 5.8–8.1 days. Limit: endocrine markers and tolerability in healthy volunteers. The study did not establish fat loss, muscle gain, improved sleep, cognitive benefit, recovery, anti-aging effects, or long-term safety.

• Human pharmacology · healthy men

  Ionescu & Frohman, 2006

  Healthy men underwent frequent overnight sampling before and one week after the long-acting analogue. GH secretion remained pulsatile, with higher pulse amplitude and greater total GH output; IGF-1 also increased. Limit: a small, short study of healthy men focused on hormone patterns—not health outcomes or therapeutic effectiveness.

• Exploratory biomarker work

  Sackmann-Sala et al., 2009

  Serum from 11 healthy young men was analyzed before and one week after administration. The investigators reported changes in several circulating proteins alongside activation of the GH/IGF-1 axis. Limit: exploratory biomarker work in a very small male sample. It cannot establish clinical benefit.

FDA’s detailed review pooled published exposure in 63 healthy adults, most of whom were men and most of whom received only one administration. Injection-site reactions were common. Other reported events included flushing or warmth, headache, diarrhea or loose stools, nausea or abdominal pain, transient low blood pressure, increased heart rate, dizziness, and an uncommon episode involving involuntary leg contractions and impaired coordination.

FDA also reviewed nonclinical findings that raised concerns about local tissue injury, genotoxic signals, and possible pituitary effects with prolonged stimulation. Those findings do not prove the same harm occurs in people, but they underline why small, short trials cannot establish chronic safety.

Increasing GH/IGF-1 can also raise questions relevant to glucose regulation, fluid retention, nerve-compression symptoms, cardiovascular risk, and conditions in which growth signaling matters. Risks may differ by chemical form, concentration, impurities, route, duration, age, and underlying health.

Fatigue, sleep problems, changes in body composition, low exercise tolerance, and perceived “low growth hormone” are nonspecific. They can reflect sleep disorders, medication effects, thyroid disease, anemia, depression, under-recovery, cardiometabolic disease, menopause or androgen changes, nutrition, or other causes.

True adult growth hormone deficiency requires specialist evaluation and validated testing. FDA noted that CJC-1295-related substances are not discussed in professional guidelines for growth hormone deficiency and that patients with complete deficiency would not be expected to respond to a secretagogue in the same way as healthy volunteers.

For weight management, FDA-approved options with established labeling and clinical outcome data are a different evidence category from investigational CJC-1295. A clinician can help distinguish a diagnosable endocrine disorder from broader wellness goals and discuss approved, monitored care.

Tesamorelin

Another GHRH analogue, but with an FDA-approved indication limited to reducing excess abdominal fat in adults with HIV-associated lipodystrophy. That approval cannot be transferred to CJC-1295.

Sermorelin

A shorter GHRH fragment with its own regulatory history and evidence limits. Similar pathway language does not make it the same intervention.

Ipamorelin

A growth hormone secretagogue acting through the ghrelin receptor rather than a GHRH analogue. Combination or “stack” claims need direct evidence.

Growth hormone

Recombinant GH is a different drug class with FDA-approved products for defined diagnoses, labeled monitoring, and known risks. It is not a benchmark that validates CJC-1295.